Pharsight

Celgene Intl patents expiration

1. Zeposia patents expiration

ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481573 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(5 years from now)

US8796318 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(5 years from now)

US11680050 CELGENE INTL Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Sep, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(5 years from now)

US10239846 CELGENE INTL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 25, 2025
New Indication (I) May 27, 2024

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: 2024-03-25

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the tr...

Dosage: CAPSULE;ORAL

More Information on Dosage

ZEPOSIA family patents

Family Patents